Takeda Pharmaceutical has announced it will discontinue all cell therapy research and development, marking a significant strategic withdrawal from a field it once considered a priority area for innovation. The Japanese pharma giant revealed on October 1 it will seek an external partner to acquire its cell therapy platforms and continue advancement of its preclinical and clinic-ready programs.
This move follows Takeda’s years of investment in gamma delta T-cell platforms, particularly after the 2021 acquisition of UK-based GammaDelta Therapeutics and subsequent purchase of Adaptate Biotherapeutics. The cell therapy programs were largely targeted at oncology and had included the discontinued TAK-007 for blood cancers, which Takeda had previously ended based on clinical data. The struggles and high costs associated with bringing cell therapies to market, coupled with mounting safety and profitability concerns, have led several major pharmaceutical companies to reassess their cell and gene therapy pipelines in recent months.
Takeda’s portfolio reprioritization will see near-term investments redirected toward small molecules, biologics, and antibody-drug conjugates—modalities the company believes can deliver innovative therapies to patients more efficiently and at greater scale. As part of the exit, Takeda will record an impairment loss of approximately 58 billion yen (nearly $395 million), mostly attributable to intangible assets linked to the gamma delta T-cell platform. Although Takeda’s preclinical research will still benefit from insights learned during its cell therapy work, the company no longer has any active clinical trials using cell therapy technologies.
The exit will impact about 137 employees and underscores the current industry trend of big pharma pulling back from cell therapy modalities amid uncertain returns and challenging development timelines.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!